Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...

On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target. In an investor note, the analyst cited ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the best stocks you’ll wish you bought sooner. As of the close of December 2, the consensus shows that analyst opinions are highly favourable ...

Chief Executive Officer — Joseph K. Belanoff Chief Business Officer — Gary Robb President, Endocrinology — Sean Maduck Chief Development Officer — William Guyer Chief Financial Officer — Atabak Mokari ...

Imagine trying to spot an object just 30 centimeters wide from hundreds of kilometers above Earth. Years ago, I remember when “satellite view” meant blurry green blobs on a screen. Now, we can see ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2025 Earnings Call Transcript November 4, 2025 Corcept Therapeutics Incorporated misses on earnings expectations. Reported EPS is $0.16 EPS, ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Tuesday reported third-quarter net income of $19.4 million. On a per-share basis, the Redwood City, ...

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need ...

ClearBridge Investments, an investment management company, released its “Clearbridge Global Value Improvers Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.